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ABSTRACT
Human DBC1 (Deleted in Breast Cancer 1; KIAA1967;
CCAR2) is a protein implicated in the regulation of
apoptosis, transcription and histone modifications.
Upon DNA damage, DBC1 is phosphorylated by
ATM/ATR on Thr454 and this modification increases
its inhibitory interaction with SIRT1, leading to p53
acetylation and p53-dependent apoptosis. Here, we
report that the inhibition of SIRT1 by DBC1 in the
DNA damage response (DDR) also depends on Chk2,
the transducer kinase that is activated by ATM upon
DNA lesions and contributes to the spreading of DNA
damage signal. Indeed we found that inactivation of
Chk2 reduces DBC1-SIRT1 binding, thus preventing
p53 acetylation and DBC1-induced apoptosis. These
events are mediated by Chk2 phosphorylation of the
11S proteasome activator REG on Ser247, which
increases REG-DBC1 interaction and SIRT1 inhibi-
tion. Overall our results clarify the mechanisms un-
derlying the DBC1-dependent SIRT1 inhibition and
link, for the first time, Chk2 and REG to the ATM-
DBC1-SIRT1 axis.
INTRODUCTION
In order to preserve genomic stability, eukaryotic cells have
evolved a complex network of signaling pathways, collec-
tively known as DNA damage response (DDR), that are
activated when cells are exposed to genotoxic lesions (1).
Key components of the DDR cascade in response to
double-strand breaks (DSBs) are the apical kinase ATM
(Ataxia Telangiectasia Mutated) and its target and effec-
tor checkpoint kinase Chk2 (2). Following DNA damage,
ATM phosphorylates Chk2 on Thr68, leading to its acti-
vation and phosphorylation of several substrates, including
p53, HDMX, PML (3), TRF2 (3,4) and KAP1 (5,6). Active
Chk2 thus amplifies the DDR signal and promotes tran-
sient cell cycle arrest to allow DNA repair or, in presence of
irreparable damages, the induction of apoptosis. The fail-
ure of these mechanisms leads to accumulation of genetic
alterations, a common feature of cancer cells (7).
The 11S proteasome activator REG binds and activates
the catalytic function of the 20S proteasome (8), promotes
the ubiquitin-independent degradation of a number of pro-
teins, including SRC-3, p21, p16 and p53 (8) and is in-
volved in the regulation of chromosomal stability (9). Most
recently, REG was found to be acetylated by CBP and
deacetylated by SIRT1, respectively, promoting or inhibit-
ingREG activity (10).Moreover, the interaction ofREG
with SIRT1 promotes its inhibition and Ub-independent
degradation (11). In addition, we have demonstrated that
REG physically binds Chk2 in human cells (12), whereas
other studies have shown that REG is phosphorylated in
anATM-dependentmanner following genotoxic stress (13).
DBC1 (Deleted in Breast Cancer 1; KIAA1967; CCAR2)
is a nuclear protein encoded by a gene originally described
as homozigously deleted in some breast cancers (14–16).
In spite of this deletion assignment, further studies showed
DBC1 overexpression in breast, esophageal, gastric and col-
orectal cancers (17–21) and loss of DBC1 increases the
death of breast cancer cells (22,23); however, DBC1 inhibits
cancer cell survival following genotoxic stress (24,25). For
these controversial effects on cancer cells, it is still unclear
whether DBC1 acts as a tumor suppressor or a tumor pro-
moter.
It is now well established that DBC1 interacts with and
negatively regulates SIRT1 (24,25), a NAD+-dependent
deacetylase able to deacetylate histone and non-histones
protein, such as the tumor suppressor p53 (26,27). DBC1-
mediated repression of SIRT1 results in increased levels of
p53 acetylation and upregulation of p53-mediated apopto-
sis after DNA damage (24,25). Previously, we and others
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reported that, in response to DNA damage, DBC1 phos-
phorylation of Thr454 by ATM and ATR enhances DBC1
binding to and inhibition of SIRT1, promoting p53 activa-
tion and induction of apoptosis (28,29). Furthermore, re-
cent studies show that, after DNA damage, kinase suppres-
sor of Ras-I (KSR1) plays a role in decreasing DBC1 phos-
phorylation of Thr454, leading to a reduced DBC1-SIRT1
interaction and a lower transcriptional activity of p53 (30).
Moreover, DBC1-SIRT1 binding is negatively regulated by
hMOF acetylation (a member of the MYST family of his-
tone acetyltransferases) of specific DBC1 residues, a pro-
cess inhibited by ATM upon DNA damage (31). Collec-
tively these results indicate that DBC1 and SIRT1 form, in
human cells, a dynamic and regulated complex.
Here, we report that beside ATM and ATR, also Chk2
kinase and REG proteasome activator are required for
SIRT1 inhibition by DBC1 and for the induction of DBC1-
dependent apoptosis, in response to etoposide-induced
DNA damage.
MATERIAL AND METHODS
Cell lines, treatments and antibodies
Human osteosarcoma U2OS cell line was cultured in
DMEM (Dulbecco’s modified Eagle’s medium, Gibco),
supplemented with 10% fetal bovine serum and 1%
penicillin/streptomycin; cells were maintained at 37◦C and
5% CO2. The proteasome inhibitor MG132 (Sigma) was
added to cells 20 min before genotoxic treatments to a fi-
nal 25Mconcentration. TheChk2 inhibitorVRX0466617
(kindly provided by Dr Minmin Yang, Pharmablock), was
added 1 h before treatments at 100 M. Etoposide (TEVA)
was used at 20MandNeocarzinostatin (Sigma) at 8.8 nM.
Cells viability was analyzed by trypan blue (Sigma) staining.
Expression vectors, siRNAs and tranfections
Vectors encoding DBC1-WT and DBC1-T454A were re-
ported in (28), FLAG-SIRT1, HA-DBC1-WT and deletion
mutants plasmids were described in (24), whereasHA-Chk2
and FLAG-Chk2 were reported in (32). FLAG-REG was
described in (12) and site directedmutagenesis to change the
REG -S247 residue to A was performed with QuikChange
II XL SiteDirectedMutagenesis Kit (Stratagene) according
to manufacturer protocol. siRNAs against DBC1, SIRT1,
Chk2 and REG were ON-TARGETplus SMARTpool
reagents and purchased from Thermo Scientific Dharma-
con. Lipofectamine 2000 (Invitrogen) and Lipofectamine
RNAiMAX (Invitrogen) were used for plasmids and siR-
NAs transfections, respectively.
Western blots and immunoprecipitations
Western blot (WB) analyses were performed with the Nu-
PAGE system (Invitrogen) and densitometric evaluations
were done with the ImageQuant 5.2 software (Molec-
ular Dynamics). REG phosphorylation analyses were
performed using Phos-Tag (Wako) at 30 M in a 10%
acrylamide gel (13). The antibodies used were: DBC1
(Bethyl Laboratories, A300–434A or Cell Signaling Tech-
nology, clone 3G4); p53 (Santa Cruz, DO-7); p53-Ac-K382,
phospho-Chk2-T68, PUMA, Cleaved PARP-1 and Cleaved
Caspase-3 (Cell Signaling Technology); FLAG (clone M2),
-Actin and SIRT1 (Sigma); HA (clone 12CA5, Roche);
REG (Transduction Laboratories). Chk2 antibody (clone
44D4/21) was previously described (33) or purchased from
MBL Intl Corp (DCS-270 and DCS-273). Immunoprecip-
itation (IP) experiments were carried out as described (12)
using cell lysates prepared in ELB buffer (150 mMNaCl, 50
mM Hepes pH 7.5, 5 mM EDTA, 0.5% NP40). After pre-
clearing with protein-G (for mouse antibodies) or protein-
A (for rabbit antibodies) coupled sepharose beads (Sigma),
proteins of interest were subjected to IP with specific anti-
bodies and analyzed by WB.
Recombinant protein production and in vitro kinase assays
Recombinant GST-DBC1, GST-REG , His-SIRT1 pro-
teins and fragments were produced in Escherichia coli and
purified. In vitro kinase reactions with catalytically active
GST-Chk2 were performed as previously reported (32).
Pull down
REG -S247 non-phospho-peptides (EKIKRPRSSNAET
LY) and phospho-peptides (EKIKRPR(p)SSNAETLY)
conjugated to agarose beads were purchased from Primm-
Biotech. Beads were incubated with cell lysates prepared
in ELB buffer and, after washing, samples were boiled in
SDS sample buffer and analyzed by western blot. For phos-
phopeptides dephosphorylation, FastAP Thermosensitive
Alkaline Phosphatase (Fermentas) was used, according to
manufacturer’s protocol.
RESULTS
Chk2 kinase is required for DBC1-dependent SIRT1 inhibi-
tion
We and others have previously shown that genotoxic stress
induces the phosphorylation by ATM/ATR of DBC1-
Thr454, promoting DBC1’s interaction with and inhibi-
tion of SIRT1 deacetylase (28,29). As the checkpoint ki-
nase Chk2, a target of ATM, catalyzes the phosphorylation
of several proteins that are also phosphorylated by ATM
(3), and upon oxidative stress promotes SIRT1 mRNA de-
cay by phosphorylating the mRNA binding protein HuR
(34), we asked whether Chk2 might also be involved in
DBC1-dependent regulation of SIRT1. For this, the acety-
lation of p53, which we found to increase following DBC1
overexpression as result of SIRT1 inhibition (28), was an-
alyzed in U2OS cells co-transfected with siRNA against
Chk2 (or siLUC control sequence) and with a vector en-
coding DBC1 (or MOCK vector). Although in unstressed
cells neither DBC1 overexpression nor Chk2 depletion af-
fected p53 acetylation (data not shown), in etoposide-
treated cells DBC1 overexpression raised p53 acetylation in
Chk2-proficient, but not in Chk2-depleted cells (Figure 1A,
compare lane 3 and 4). To verify that this event is not caused
by Chk2-dependent induction of SIRT1 protein, possibly
mediated by HuR, we performed western blot analysis of
control and Chk2-depleted cells expressing ectopic DBC1,
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Figure 1. Chk2 is required for DBC1-dependent SIRT1 inhibition and induction of p53-mediated apoptosis after DNA damage in U2OS cells. Western
blot analysis of total cell extracts from cells transfected with control or Chk2 siRNA and then with MOCK- or DBC1-encoding vectors. In (A) cells were
incubated with 20 MMG132 for 20 min prior to treatment with etoposide for 1 h and analyzed for p53 acetylation. Densitometric analyses (relative fold)
show the ratios of acetylated p53-K382/total p53 normalized to the value of MOCK-transfected cells. In (B) and (C) cells were respectively treated with
etoposide for 6 and 30 h and PUMA levels and apoptotic markers were analyzed. The same cells of experiment C were used to evaluate the percentage of
dead cells by trypan blue staining. Values are mean ± SD from three independent experiments. Significant P-value is indicated (D).
but no significant differences in SIRT1 protein levels were
found among samples (Supplementary Figure S1).
As DBC1-induced p53 acetylation promotes p53-
dependent transcriptional activity and apoptosis (28), we
examined the effect of Chk2 depletion on these events.
We found in etoposide-treated DBC1-overexpressing cells
a marked PUMA accumulation and cleavage of both
PARP-1 and Caspase-3 in Chk2-proficient cells, but not
in Chk2-deficient cells (respectively, Figure 1B and C,
compare lanes 5 and 7 and lanes 7 and 8). Concordant
with these biochemical findings, the increased etoposide-
induced cell death, due to DBC1 overexpression, was
antagonized by Chk2 ablation (Figure 1D). Curiously, we
also found that Chk2 silencing prevents PUMA induction
and Caspase-3 cleavage (Figure 1B and C) and that Chk2
depletion alone cannot affect etoposide-induced apoptosis
(Figure 1D).
Since also ectopic Chk2 can promote apoptosis (35,36),
we verified whether the DBC1-induced cell death might be
attributed to an increased Chk2 activity. However, we did
not find any effect of DBC1 ablation on the rate of Chk2-
induced cell death (Supplementary Figure S2). Notably, we
found that DBC1 ablation did not reduce apoptosis induc-
tion, contrary to previous reports (24,25), even though p53
acetylation and PUMA expression were reduced (Supple-
mentary Figure S2), and PARP cleavage induced (Supple-
mentary Figure S2). The balance among these apoptotic
factors could possibly explain why DBC1 absence does not
affect cell death in our experimental conditions.
To determine whether Chk2 inhibition has the same ef-
fect on DBC1-SIRT1 regulation as Chk2 knockdown, ex-
periments were performed in U2OS cells overexpressing
DBC1 that, prior to etoposide exposure, were pre-treated
with VRX0466617 (hereafter referred to VRX), a selective
inhibitor of Chk2 (37). The results showed that the catalytic
activity of Chk2 is indispensable forDBC1-mediated induc-
tion of p53 acetylation and apoptosis (Supplementary Fig-
ure S3).
Collectively, besides ATM/ATR, the activity of Chk2 ki-
nase is also required for DBC1-mediated SIRT1 inhibition,
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Figure 2. Chk2 kinase activity promotes DBC1-SIRT1 binding in response to DNA damage in U2OS cells. DBC1 was immunoprecipitated from cells
transfected with control or Chk2 siRNA and treated or not with etoposide (A) or from cells pretreated with VRX and then exposed to etoposide (B);
SIRT1 presence in immunocomplexes was determined by western blot (left) and total lysates (right) were analyzed for protein levels. Relative fold indicates
the densitometric quantification of SIRT1 co-immunoprecipitated with DBC1; data from etoposide-treated cells were normalized to those from untreated
samples. (C) Cells were transfected with DBC1, FLAG-SIRT1 and increasing levels of HA-Chk2-encoding vectors and FLAG-SIRT1 was immunopre-
cipitated; immunocomplexes (left) and protein levels in total cell extracts (left) were analyzed by western blot with the indicated antibodies. (D) Cells were
transfected with DBC1-WT or T454A mutant, FLAG–SIRT1- and HA-Chk2-encoding vectors and FLAG-SIRT1 was immunoprecipitated; immuno-
complexes (left) and protein levels in total cell extracts (right) were analyzed by western blot with the indicated antibodies. WCE, total cell extracts; IP,
immunoprecipitates; PC, pre-cleared negative control.
ensuing acetylation/activation of p53, and finally apopto-
sis.
Chk2 regulates DBC1-SIRT1 association
To investigate the mechanism involved in SIRT1 inhibition
by DBC1 and Chk2, we initially determined whether Chk2
depletion could affect DBC1 phosphorylation on Thr454,
but, as shown in Supplementary Figure S4, no significant
differences were found between control and siChk2 trans-
fected cells before and after etoposide exposure. We then
analyzed DBC1-SIRT1 association in response to DNA
damage in control and Chk2 depleted U2OS cells. Al-
though DBC1 and SIRT1 protein levels were similar in
all cell extracts (Figure 2, right panel), we found that
etoposide treatment increased the amount of SIRT1 that
co-immunoprecipitated with DBC1, as already reported
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(28,29), but no increase was seen in Chk2-silenced cells
(Figure 2A left, compare lane 2 with lane 4). Similar re-
sults were obtained analyzing the co-immunoprecipitation
between DBC1 and SIRT1 in FLAG-DBC1 overexpress-
ing cells depleted of Chk2 by siRNA (Supplementary Fig-
ure S5), thus excluding an influence of DBC1 expression
levels on Chk2 regulation of DBC1-SIRT1 complex for-
mation. In addition co-immunoprecipitation (co-IP) assays
performed in the presence of VRX indicated that the cat-
alytic activity of Chk2 is necessary for increasing DBC1-
SIRT1 binding in response to etoposide (Figure 2B, left),
even if VRX treatment alone seems to increase the as-
sociation between these two proteins. However, since the
DBC1-SIRT1 association is regulated also by phosphoryla-
tive events, it is possible that this phenomenon could be an
effect of Chk2 inhibition on phosphatases activity as pre-
viously reported (38). To further verify the role of Chk2
in promoting DBC1-SIRT1 association, U2OS cells were
transfected with fixed amounts of vectors encoding DBC1
and FLAG-SIRT1, and increasing amounts of a vector en-
coding HA-Chk2, which is known to homodimerize and
become active when overexpressed (39). FLAG-SIRT1 im-
munocomplexes were then analyzed by western blot and,
as expected, DBC1 binding to SIRT1 increased with the
expression of Chk2 (Figure 2C, left). Similar experiments
were performed to determine the role of Thr454 phospho-
rylation in Chk2-mediated increase of DBC1-SIRT1 associ-
ation andwe found that Chk2 overexpression cannot induce
the binding of DBC1-T454A to SIRT1 (Figure 2D). Alto-
gether, these findings suggest that Chk2 kinase promotes
the physical association betweenDBC1 and SIRT1 in DNA
damaged cells and, for this, the phosphorylation of DBC1
on Thr454 by ATM/ATR is also required.
Chk2 binds DBC1 and SIRT1 in human cells
We next carried out co-IP experiments to determine
whether Chk2 physically interacts withDBC1 and SIRT1 in
human cells and to what extent DNA damage regulates this
interaction. For this, Chk2 was immunoprecipitated from
U2OS cells treated or untreated with neocarzinostatin or
etoposide and immunoblotted for DBC1 and SIRT1, and,
as shown in Figure 3A, Chk2 immunoprecipitates, but not
negative controls, showed an interaction with both DBC1
and SIRT1 that weakly increased after DNA damage. Ad-
ditional co-IP experiments confirmed the presence of Chk2
in DBC1 immunocomplexes from U2OS cells (Figure 3B),
and in SIRT1 immunoprecipitates prepared from other two
cell lines (Figure 3C).
We next analyzed whether DBC1 could affect Chk2-
SIRT1 association. U2OS cells were therefore transfected
with siRNA to knockdown DBC1 and SIRT1 immuno-
complexes analyzed for Chk2. As shown in Figure 3D
right, DBC1 depletion had no effect on Chk2-SIRT1 bind-
ing. Similarly, SIRT1 knockdown had no effect on DBC1-
Chk2 association, either before or after DNA damage (Fig-
ure 3E).
Together, these co-IP studies are consistent with a model
where DBC1, SIRT1 and Chk2 form a protein complex in
human cells, and loss of any one of these proteins does not
impair the binding between the other two.
We then asked whether DBC1 and SIRT1 could be candi-
date substrates for Chk2 kinase. To verify this, we initially
set up in vitro kinase assays with recombinant GST-Chk2
(40) and GST-DBC1 as substrate, and although GST-Chk2
was able to autophosphorylate and to target aGST-Cdc25C
fragment, used as positive control, GST-DBC1 not only re-
mained unphosphorylated, but quite surprisingly inhibited
Chk2 activities (Supplementary Figure S6). Similar results
were obtained using His-DBC1 (data not shown), indicat-
ing that this inhibitory effect on Chk2 kinase is not due to
GST-induced multimerization. Other in vitro Chk2 kinase
assays performed with four DBC1 deletion fragments and
full length SIRT1 showed no significant phosphorylation of
these recombinant substrates (Figure 3F), but they allowed
to map the N-terminus sequence (a.a. 1–229) of DBC1 as
being responsible for the inhibition of Chk2 autophospho-
rylation and activity towards Cdc25C (Figure 3F, lane 1).
It should be noted however that, in cells, deletion of the N-
terminus region ofDBC1 (a.a. 1–179) is sufficient to abolish
DBC1 binding to Chk2 which maps on Chk2 catalytic do-
main (Supplementary Figure S7).
Collectively, these data indicate that, at least in vitro,
DBC1 and SIRT1 are not substrates of Chk2 kinase and
that the N-terminus of DBC1 inhibits the activity of Chk2
by binding to its kinase domain.
REG proteasome activator interacts with DBC1 and is a
Chk2 phosphorylation target
We previously demonstrated that Chk2 interacts with the
proteasome activator REG (12), while, more recently, it
was shown that SIRT1 deacetylates REG and reduces its
activity (10), and that the interaction of these proteins pro-
motes SIRT1 degradation and inhibition by substrates dis-
placement (11). These observations raise the possibility of
interplay between REG , Chk2, SIRT1 and DBC1. To test
this, we initially verified whether DBC1 and REG asso-
ciate in human cells and found, in co-IP assays, that en-
dogenous REG and DBC1 reciprocally immunoprecipi-
tate each other (Figure 4A and B) both before and after
DNA damage (Figure 4B).
As REG protein contains two predicted consensus mo-
tifs for Chk2 phosphorylation on Ser24 and Ser247 (Sup-
plementary Figure S8), we checked in in vitro kinase assays
the activity of Chk2 towards full length and deleted forms
of recombinant GST-REG . The results (Figure 4C) evi-
denced a phosphorylation signal on GST-REG and GST-
REG 115–254 fragment, but not on GST-REG 1–115, sug-
gesting Ser247 as a Chk2 phosphosite. Phos-tag gel analysis
previously demonstrated that genotoxic damage induces an
ATM-dependent phosphorylation of REG (13). To deter-
mine whether Chk2 also phosphorylates REG in vivo, cell
extracts prepared from etoposide-treated or untreated sam-
ples, with or without the Chk2 inhibitor VRX, were exam-
ined with the Phos-tag western blot technique. The results
show in etoposide-treated cells the presence of a slower mi-
grating REG form (Figure 4D), in accordance with ear-
lier findings (13), markedly attenuated by VRX. The ab-
sence of this form in cells where REG was knocked down
by siRNA validated the results (Supplementary Figure S9).
We also analyzed the mobility shift of FLAG-REGWT
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Figure 3. Chk2 interacts with DBC1 and SIRT1 in human cells. (A–C) Co-Ip experiments demonstrating the association of Chk2 with DBC1 and SIRT1,
before and after DNA damage, in different cell lines. WCE, total cell extracts; IP, immunoprecipitates; PC, pre-cleared negative control. (D) U2OS cells
were transfected with control or DBC1 siRNA and endogenous SIRT1 was immunoprecipitated. Total protein levels (left) and Chk2 protein in immuno-
complexes (right) were determined by western blot. (E) Chk2 was immunoprecipitated from control or siSIRT1 transfected cells before and after etoposide
exposure. Total protein levels and co-Ip with DBC1 were analyzed by WB. Asterisk indicates SIRT1 specific band. (F) In vitro kinase assays with recom-
binant active Chk2 and GST-DBC1 deletion mutants, His SIRT1 and GST-Cdc25C (positive control) as substrates.
and FLAG-REGS247A and found that the intensity of the
slower migrating band is strongly attenuated in cells ex-
pressing FLAG-REGS247A mutant protein (Figure 4E).
Together, these results indicate that DBC1 and REG in-
teract in human cells and that Chk2 can phosphorylate a
fraction of the total pool of REG in human cells on Ser
247.
SIRT1 inhibition by DBC1 is REG-dependent
The potential role played by REG in DBC1-dependent
inhibition of SIRT1 was analyzed in DBC1-overexpressing
U2OS cells transfectedwith siRNAagainst REG or a con-
trol sequence, and the results showed that REG depletion
reduces the DBC1-dependent increase in p53 acetylation
(Figure 5A). Moreover, when we overexpressed REGWT
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Figure 4. REG interacts with DBC1 and is phosphorylated by Chk2. (A) DBC1 is present in REG immunocomplexes from U2OS cells. (B) DBC1 was
immunoprecipitated fromU2OS cells before and after etoposide exposure. The presence ofREG was determined by immunoblot.WCE, total cell extracts;
IP, immunoprecipitates; PC, pre-cleared negative control. (C) In vitro kinase assays with recombinant active GST-Chk2 and full length or deletion mutants
GST-REG as substrates. GST-Cdc25C was used as positive control. (D) Phos-Tag gel analyses of REG molecular shifts in response to etoposide and
in the absence or presence of the Chk2 inhibitor VRX. (E) U2OS cells were transfected with vectors encoding FLAG-REGWT and FLAG-REGS247A
and treated or untreated with etoposide. Molecular shifts of the ectopic proteins were analyzed by phos-tag gel.
or REGS247A in control or Chk2 silenced U2OS cells, we
detected an increase in p53 acetylation, upon etoposide,
only with the ectopic wild-type protein and in Chk2 pro-
ficient cells (Figure 5B), clearly indicating that SIRT1 inhi-
bition by DBC1 requires REG phosphorylated on S247
by Chk2. Accordingly, when we analyzed the role of REG
phosphorylation in PUMA protein induction and apop-
tosis, we found that the expression of REGWT, but not
of REGS247A, can promote the accumulation of PUMA
and the increase of U2OS cell death (Figure 5C–E). To fur-
ther investigate the mechanism underlying REG mediated
DBC1-dependent SIRT1 inhibition, we analyzed DBC1-
SIRT1 complex in REG silenced cells. We found that, like
Chk2 depletion, REG silencing prevents the increase of
the association between DBC1 and SIRT1 upon etoposide
exposure (Figure 5F).
We then determined the function of REG phosphory-
lation on Ser247 in DBC1-REG complex formation and
found that, whereas the binding of DBC1 to REGWT in-
creases in response to DNA damage, the association with
REGS247A is reduced (Figure 5G left, compare lanes 4
and 6). To further address this point we performed pull-
down assays by incubating cell lysates from untreated and
etoposide treated cells with REG peptides phosphory-
lated or not on Ser247 (respectively, REG -pS247 and
REG -S247). We found that DBC1 binds better the non-
phosphorylated peptide than the phosphorylated one, but
whereas the association between DBC1 and REG -S247
is reduced upon DNA damage, the binding of DBC1 with
REG -pS247 is maintained in response to etoposide treat-
ment (Supplementary Figure S10). Similar results were ob-
tained also analyzing the binding of DBC1 to the REG
phosphorylated peptide that had been pretreatedwith phos-
phatase (Supplementary Figure S10). Collectively these
data suggest that REG -Ser247 phosphorylation promotes
its association with DBC1 and contributes to the DBC1-
mediated inhibition of SIRT1.
DISCUSSION
Here, we report that catalytically active Chk2 is required
for DBC1-mediated SIRT1 deacetylase inhibition and p53-
dependent apoptosis. This phenomenon is not achieved
through Chk2-dependent alterations of DBC1 phosphory-
lation on Thr454, but through a mechanism in which Chk2
potentiates the DBC1-SIRT1 binding and consequently
SIRT1 inhibition. Indeed this event is abolished by deple-
tion or chemical inhibition of Chk2 and, as we demon-
strated, it is not influenced by DBC1 expression levels, even
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Figure 5. REG mediatesDBC1 andChk2-dependent SIRT1 inhibition. (A)U2OS cells were transfectedwith control orREG siRNA, thenwithMOCK-
or DBC1-encoding vectors and exposed to etoposide for 3 h. p53-acetylation levels were determined by western blot. (B) Control or Chk2 silenced cells
overexpressing FLAG-REGWT or FLAG-REGS247A were expose to etoposide and analyzed for p53 acetylation. In (A) and (B) relative fold indicates
the ratios of acetylated p53-K382/total p53 normalized to the value of MOCK-transfected cells. In (C) and (D) cells were transfected with MOCK-,
FLAG-REGWT- and FLAG-REGS247A-encoding vectors treated respectively with etoposide for 6 and 30 h and PUMA levels and apoptotic markers
were analyzed. (E) The same cells of experiment (D) were used to evaluate the percentage of dead cells by trypan blue staining. (F) Co-IP experiments
of DBC1 and SIRT1 in REG -depleted cells (left) and western blot analysis of total protein levels in the same extracts (right) (G) Co-IP experiments of
DBC1 and FLAG-REGWT or FLAG-REGS247A (left) and western blot analysis of total protein levels in the same extracts (right). Arrow indicates
FLAG-positive bands.
if we found that Thr454 phosphorylation is necessary for
the Chk2mediated increase ofDBC1-SIRT1 binding.How-
ever, although we noticed in Chk2-depleted cells reduced
level of both PUMA protein and cleaved caspase-3, as pre-
viously reported in (41,42), we curiously found that Chk2
depletion or chemical inhibition has no effect on etoposide-
induced p53 acetylation and apoptosis, as demonstrated by
cleaved PARP1 levels and by the percentage of dead cells.
This event could possibly be explained by the redundancy
of cell cycle checkpoint pathways that couldmask the apop-
totic defect caused by Chk2 inhibition, as previously re-
ported in normal cells for VRX treatment (37). Alterna-
tively, we can also suggest the existence of a Chk2 inde-
pendent way to etoposide-induced apoptosis, which does
not require caspase-3 cleavage or the induction of PUMA
protein. Instead, the increased cell death detectable upon
DBC1 overexpression and etoposide exposure is depen-
dent on Chk2 and established on a pathway which requires
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Figure 6. Graphical representation of DBC1 regulation in the DDR. In
response to DNA damage ATM contributes to p53 activation in different
ways, by phosphorylation of (i) p53 on Ser15, (ii) DBC1 onThr454 and (iii)
Chk2 on Thr68. Chk2, activated by ATM, then phosphorylates REG ,
promoting DBC1-REG association and SIRT1 inhibition. These events
finally lead to p53 activation and p53-dependent apoptosis.
PUMA induction and caspase-3 cleavage. This route seems
to be specifically based on the increase of p53 acetylation
by DBC1-dependent SIRT1 inhibition. It should be noted,
however, that neither DBC1 nor SIRT1 appeared to be
phosphorylated by Chk2 in vitro, although we cannot defi-
nitely exclude the occurrence of these events in vivo, where
other factors might favor Chk2 activity toward these sub-
strates. Curiously, when we analyzed the role of DBC1 in
Chk2 induced apoptosis, we found that DBC1 depletion
does not affect cell death, as previously reported, although
it reduces p53 acetylation and PUMA induction, but not
PARP1 cleavage. This phenomenon might be ascribed to
different experimental conditions, which can result in dif-
ferent effects of DBC1 depletion. Indeed, recently, other
papers reported that DBC1 absence, in response to vari-
ous stimuli, enhances cell death (43–45), thus supporting a
model in which DBC1 can modulate apoptosis depending
on the cellular context, type of damage and on the duration
of genotoxic stress.
It was recently found that the activity of the 11S pro-
teasome activator REG is regulated by CBP and SIRT1-
dependent acetylation/deacetylation (10) and that REG
itself is implicated in SIRT1 degradation and inhibition
(11). Since we have previously found that REG binds
Chk2 (12), we postulated that this protein could be the tar-
get of Chk2 activity involved in SIRT1 inhibition by DBC1.
In accordance with this, we found that, upon DNA dam-
age Chk2 phosphorylates REG on Ser247, both in vitro
and in vivo, and that this modification promotes p53 acety-
lation, PUMA protein induction and apoptosis. Indeed, al-
though REG was found not to be implicated in the reg-
ulation of SIRT1 activity towards p53 (11), in our cellu-
lar system we demonstrated that REG and its phospho-
rylation on Ser247 by Chk2 are necessary for the DBC1-
dependent increase of p53-acetylation, further corroborat-
ing the hypothesis that this proteasome activator subunit
could be the missing link between DBC1 and Chk2 to-
ward SIRT1 activity inhibition. Additionally, we found that
REG , like Chk2 and DBC1-Thr454 phosphorylation, is
required to increase DBC1-SIRT1 binding and SIRT1 ac-
tivity inhibition and that REG phosphorylation by Chk2
is necessary to increase REG -DBC1 binding in response
to DNA damage. Accordingly, pull down experiments with
phosphorylated and unphosphorylated peptides spanning
REG -Ser247 indicated that the association of DBC1 with
the non-phosphorylated peptide decreases upon etoposide
treatment, whereas the binding with the peptide phospho-
rylated on Ser247, although strongly reduced, is not af-
fected by DNA damage treatment. These results suggest
that REG -Ser247 phosphorylation by Chk2 can induce
a conformational change in REG protein that favors its
binding to DBC1. Alternatively it is also possible that this
phosphorylation could promote REG interaction with
other protein(s) that then lead to the increased DBC1-
REG association. The strong interaction between DBC1
and REGS247A detectable in untreated cells could be
due to a better affinity of the unphosphorylated REG
for the DBC1 form present in untreated cells, as revealed
also by the pull down assay. Indeed it is possible that over-
expressed REG -WT could be partially phosphorylated
on Ser247, like other overexpressed phosphoproteins, and
that this phosphorylation could affect its association with
DBC1 in untreated cells. Upon DNA damage, both DBC1
and REG are characterized by post-translational modifi-
cations and themodifiedDBC1 could strongly interact with
the phosphorylated REG , but not with the unphosphory-
lated protein.
Thus, according to our model, following DNA damage
ATMphosphorylates p53-S15,DBC1-T454 andChk2-T68,
inducing p53 stabilization, DBC1-SIRT1 binding andChk2
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activation and phosphorylation of REG -Ser247. These
events enhance DBC1-REG complex formation which,
in turn, further increases its binding to and inhibition of
SIRT1, finally leading to p53-dependent apoptosis (Fig-
ure 6).
In summary, we demonstrated that DBC1 promotes
apoptosis by SIRT1 inhibition and that this phenomenon is
regulated by the ATM-Chk2-REG axis (Figure 6). With
these results we shed new light into the role of DBC1 in the
cellular response to DNA damage.
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